Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Barrett Esophagus: early-phase trial registry
18 of 33 indexed Barrett Esophagus trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #463 of 28,707 conditions by registered trial count.
33 US clinical trials · 18 currently recruiting · #463 of 28,707 conditions by registered trial count
Barrett Esophagus: 33 US clinical trials tracked, 18 recruiting.
Barrett Esophagus is the subject of 33 registered US clinical trials on ClinicalTrials.gov, 18 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 3 of these trials.
Enrollment posture brief
Registry condition barrett-esophagus
OPEN 18 | RECR 55% | LATE 0 | EARLY 3 | RANK #463 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)
Barrett Esophagus lists 18 open slots (55% of 33 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Barrett Esophagus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Barrett Esophagus is recruiting above its size-band peers.
18 of 33 indexed trials (54.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Barrett Esophagus trials is spread across many organizations.
University of Colorado, Denver accounts for 3 of 33 trials (9.1%). 23 distinct sponsors appear on at least one study for this condition label.
-
Typical Barrett Esophagus enrolment sits around 275 participants.
Median target enrolment is 275 among the 33 trials that report a genuine target (sentinel values excluded). 11 of those (33.3%) plan for fewer than 100 participants.
-
Barrett Esophagus splits between interventional and observational designs.
20 interventional and 13 observational studies make up this index (60.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
33 total, page 1 of 1
Clinical Utility of WATS3D: A 5-Year Prospective Study
CDx Diagnostics
NCT04312633
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Dana-Farber Cancer Institute
NCT05463796
EsophaCap for the Detection of Early Esophageal Carcinoma
Johns Hopkins University
NCT04214119
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
University of Colorado, Denver
NCT05530343
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
Mayo Clinic
NCT03961945
Endoscopic Submucosal Dissection (ESD)
AdventHealth
NCT05468008
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
Case Comprehensive Cancer Center
NCT06687603
Non-Endoscopic Detection of Barrett's Esophagus Using Methylation Biomarkers on EndoSign® Cell Collection Device Samples
Cyted Health
NCT06803927
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
University of Colorado, Denver
NCT05753748
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
University of Colorado, Denver
NCT06693622
Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux
Louis Stokes VA Medical Center
NCT06746623
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
Mayo Clinic
NCT06071845
Longitudinal Oral Microbiome Sampling for BE
Columbia University
NCT05133102
Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus
Northwestern University
NCT05056051
Obeticholic Acid for Prevention in Barrett's Esophagus
National Cancer Institute (NCI)
NCT04939051
Pilot Study for OCT Guided In Vivo Laser Capture Microdissection for Assessing the Prognosis of Barrett's Esophagus
Massachusetts General Hospital
NCT03830801
Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype
Denver Health and Hospital Authority
NCT06532734
Impact of RFA on Esophageal Distensibility and Mucosal Impedance
Mayo Clinic
NCT07126535
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus
Johns Hopkins University
NCT00431756
Coordinating Center: Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy
Massachusetts General Hospital
NCT03459339
Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System
Pentax Medical
NCT02514525
Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy
Massachusetts General Hospital
NCT02994693
Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)
University of North Carolina, Chapel Hill
NCT03554356
GCC Agonist Signal in the Small Intestine
University of Wisconsin, Madison
NCT05107219
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
National Cancer Institute (NCI)
NCT02521285
HALO Patient Registry: Ablation of Barrett's Esophagus
Medtronic - MITG
NCT00848237
trūFreeze® Spray Cryotherapy Patient Registry
US Endoscopy Group
NCT01802203
Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years
Covidien, GI Solutions
NCT00489268
An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy
Donald Mathews
NCT02310230
The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)
Columbia University
NCT05524844
OCT Pilot in Esophagus
Duke University
NCT03434834
a/LCI-OCT Pilot in Esophagus
Duke University
NCT04392167
Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease
OHSU Knight Cancer Institute
NCT02890979
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Barrett Esophagus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Barrett Esophagus trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Barrett Esophagus page
33 registered trials, 18 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 18 Barrett Esophagus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Colorado, Denver sponsors the most Barrett Esophagus trials on record, review their full trial history before evaluating a specific study. See University of Colorado, Denver's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Barrett Esophagus condition card totals 33 registered trials; most-linked intervention Esophagogastroduodenoscopy; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.